Skip to main content
Clinical Trials/JPRN-jRCT2080220398
JPRN-jRCT2080220398
Unknown
Phase 3

Investigation of Safety and Efficacy of Budesonide Inhalation Suspension in the Long-Term Use in Japanese Children With Bronchial Asthma (Open Long-Term Extension Study Following Study SD-004-0765

AstraZeneca0 sitesJune 7, 2007
ConditionsAsthma

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Asthma
Sponsor
AstraZeneca
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 7, 2007
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Ages Eligible for Study: 13 Months \- 65 Months
  • Genders Eligible for Study: Both
  • Inclusion Criteria:
  • 1\. Clinical benefit from continued treatment with budesonide inhalation suspension was expected in patients with bronchial asthma participating in study SD\-004\-0765, as judged by the investigator(s) at the completion of that study (Visit 11, Week 24\), and the patient's caregiver wished the continued treatment with budesonide inhalation suspension
  • 2\. A written consent to participate in this study had been obtained from the patient's legal representative (a person who exercises parental authority for the patient, or if no one was applicable, a guardian: in principle, the patient's parent).
  • 3\. The patient was younger than 5 years old. Patients aged 5 years could be included in this study if no other effective treatment for the patient's bronchial asthma was available as judged by the investigator(s).

Exclusion Criteria

  • 1\. Concurrent severe diseases of liver, kidney, heart or other complications.
  • 2\. 2\. Contra\-indications (eg, known or suspected allergy) to budesonide or excipients contained in the investigational product.
  • 3\. Other conditions, in which the investigator(s) judges patient's participation in this study inappropriate.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Safety and efficacy of Budesonide administration after endoscopic balloon dilation for Crohn's disease patients with intestinal stenosisCrohn's disease
JPRN-jRCT1051190043Takehara Tetsuo15
Completed
Not Applicable
Safety and efficacy of Budesonide administration after endoscopic ballon dilation for Crohn disease patients with intestinal stenosisCrohn&#39s disease
JPRN-UMIN000031839Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology17
Recruiting
Phase 3
Effectiveness of the Treatment With Budesonide Nebuliser among Patients with Acute Asthma
IRCT20170531034256N2Shahid Beheshti University of Medical Sciences70
Recruiting
Not Applicable
Investigation of the safety and efficacy of Budesonide ( Zentacort Capsules ) in patients with Crohn's diseaseCrohn's disease
JPRN-jRCT1080224091ZERIA Pharmaceutical Co., Ltd.200
Active, not recruiting
Phase 1
Efficacy and safety of inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia.This trial will be conducted in a population of preterm infants who are at high risk of developing BPD. It will not only enroll infants requiring mechanical ventilation, but also infants on nasal ventilation or continuous positive airway pressure (CPAP). The latter group does not appear to be significantly affected by lung disease shortly after birthhowever, it is at high risk of developing the new BPD.MedDRA version: 8.1 Level: PT Classification code 10006475 Term: Bronchopulmonary Dysplasia
EUCTR2009-012203-26-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)850